Academic Journal
The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
| العنوان: | The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis |
|---|---|
| المؤلفون: | Louise Buonalumi Tacito Yugar, Luis Gustavo Sedenho-Prado, Isadora Maria Castilho da Silva Ferreira, Cleide Aparecida Moreira Silva, Andrei C. Sposito, Cintia Cercato |
| المصدر: | Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-9 (2024) |
| بيانات النشر: | BMC |
| سنة النشر: | 2024 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Nutritional diseases. Deficiency diseases, RC620-627 |
| الوصف: | Background Glucagon-like peptide 1 receptor agonists have been proven to be effective in adults with diabetes and children with obesity. However, children with type 2 diabetes constitute an underrepresented subpopulation with limited treatment options. This meta-analysis aimed to determine more precise estimates of the efficacy and safety of glucagon-like peptide-1 agonists in pediatric type 2 diabetes mellitus. Methods Three databases were searched (PubMed, Embase, and Cochrane Central Register of Controlled Trials) for trials published until the end of March 2024. The search indexing terms included 3 categories: [1] type 2 diabetes mellitus [2], youth, and [3] glucagon-like peptide-1 receptor agonist (GLP-1 RA). Randomized controlled trials in youth with type 2 diabetes (age ≤ 18 years) that assessed anthropometric and metabolic parameters were included. A total of 1119 nonduplicate studies were retrieved, and 137 full-text articles were screened. The data were analyzed using mean differences (MDs) with 95% CIs and odds ratios (ORs) with 95% CIs. For outcomes with low heterogeneity, a fixed-effects model was used. Otherwise, we applied a random effects model. Our outcomes were Hb1Ac, fasting blood glucose (FBG), blood pressure, weight, and side effects. Results Five studies comprehending 415 children and adolescents were included. On average, GLP-1 RA reduced HbA1c levels (-1.01%; 95% CI, -1.26 to -0.76), fasting blood glucose levels (-1.88 mmol/L; 95% CI, -2.51 to -1.26), and body weight (-1.6 kg; 95% CI, -2.83 to -0.36). No significant reductions in systolic blood pressure (MD -0.19 mmHg; 95% CI, -3.9 to 3.52 mmHg) or diastolic blood pressure (MD 0.3 mmHg; 95% CI, -2.33 to 2.93 mmHg) were observed. Despite a higher incidence of side effects, withdrawal rates from the studies remained low. Conclusions Within this specific population, GLP-1 RAs exhibit a notable association with substantial reductions in HbA1c, FBG, and body weight. The administration of these medications is concurrent with an ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1758-5996 |
| Relation: | https://doi.org/10.1186/s13098-024-01337-5; https://doaj.org/toc/1758-5996; https://doaj.org/article/18956034e24945b1bf7705ef94d8e458 |
| DOI: | 10.1186/s13098-024-01337-5 |
| الاتاحة: | https://doi.org/10.1186/s13098-024-01337-5 https://doaj.org/article/18956034e24945b1bf7705ef94d8e458 |
| رقم الانضمام: | edsbas.5052FD89 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 17585996 |
|---|---|
| DOI: | 10.1186/s13098-024-01337-5 |